Monte Rosa Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $5.92
- Today's High:
- $6.05
- Open Price:
- $6.05
- 52W Low:
- $4.4
- 52W High:
- $10.96
- Prev. Close:
- $6.04
- Volume:
- 118398
Company Statistics
- Market Cap.:
- $307.89 million
- Book Value:
- 4.308
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -25.7%
- Return on Equity TTM:
- -48.6%
Company Profile
Monte Rosa Therapeutics Inc had its IPO on 2021-06-24 under the ticker symbol GLUE.
The company operates in the Healthcare sector and Biotechnology industry. Monte Rosa Therapeutics Inc has a staff strength of 133 employees.
Stock update
Shares of Monte Rosa Therapeutics Inc opened at $6.05 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $5.92 - $6.05, and closed at $5.95.
This is a -1.49% slip from the previous day's closing price.
A total volume of 118,398 shares were traded at the close of the day’s session.
In the last one week, shares of Monte Rosa Therapeutics Inc have slipped by -4.03%.
Monte Rosa Therapeutics Inc's Key Ratios
Monte Rosa Therapeutics Inc has a market cap of $307.89 million, indicating a price to book ratio of 1.4266 and a price to sales ratio of 0.
In the last 12-months Monte Rosa Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-127686000. The EBITDA ratio measures Monte Rosa Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Monte Rosa Therapeutics Inc’s operating margin was 0% while its return on assets stood at -25.7% with a return of equity of -48.6%.
In Q2, Monte Rosa Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Monte Rosa Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.55 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Monte Rosa Therapeutics Inc’s profitability.
Monte Rosa Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.8916. Its price to sales ratio in the trailing 12-months stood at 0.
Monte Rosa Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $278.62 million
- Total Liabilities
- $19.09 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $6.51 million
- Dividend Payout Ratio
- 0%
Monte Rosa Therapeutics Inc ended 2024 with $278.62 million in total assets and $0 in total liabilities. Its intangible assets were valued at $278.62 million while shareholder equity stood at $213.65 million.
Monte Rosa Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $19.09 million in other current liabilities, 5000.00 in common stock, $-297752000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $47.03 million and cash and short-term investments were $203.07 million. The company’s total short-term debt was $2,667,000 while long-term debt stood at $0.
Monte Rosa Therapeutics Inc’s total current assets stands at $208.10 million while long-term investments were $0 and short-term investments were $156.04 million. Its net receivables were $1.15 million compared to accounts payable of $5.31 million and inventory worth $0.
In 2024, Monte Rosa Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $6.51 million.
Comparatively, Monte Rosa Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.95
- 52-Week High
- $10.96
- 52-Week Low
- $4.4
- Analyst Target Price
- $19.63
Monte Rosa Therapeutics Inc stock is currently trading at $5.95 per share. It touched a 52-week high of $10.96 and a 52-week low of $10.96. Analysts tracking the stock have a 12-month average target price of $19.63.
Its 50-day moving average was $6.6 and 200-day moving average was $6.92 The short ratio stood at 25.34 indicating a short percent outstanding of 0%.
Around 84.3% of the company’s stock are held by insiders while 8115.7% are held by institutions.
Frequently Asked Questions About Monte Rosa Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn’s disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.